Work

Main results of the First-In Human single ascending dose phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2) in glaucoma filtration surgery

Year: 2017

Type: article

Source: Investigative Ophthalmology & Visual Science

Authors: Bogomil Voykov, Hagen Thieme, Katharina Bell, Melanie Weigel, Guilia Renieri, Barbara Wilhelm, Katrin Lorenz, Petra Fettes, Eugen Leo, Norbert Pfeiffer

Institutions: Universitätsklinikum Tübingen, Otto-von-Guericke-Universität Magdeburg, University Medical Center of the Johannes Gutenberg University Mainz, STZ eyetrial, Isarna Therapeutics (Germany)

Language: English

Topic: Glaucoma and retinal disorders

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850

OpenAlex ID: W2739802673

FWCI: 0.8

Cites:

Cited by: 3

Related to: 10